Camurus launches Buvidal® weekly and monthly in Portugal

In the beginning of May 2025, Camurus introduced Buvidal^® (buprenorphine) prolonged-release solution for subcutaneous injection to the Portuguese market, presenting an innovative and flexible treatment alternative for patients with opioid dependence. The product offers a flexible treatment regimen with both weekly and monthly doses, tailored to address the varied needs of those struggling with opioid dependence.  

“Buvidal is an innovative, patient-centered treatment that may significantly enhance the daily lives of people battling opioid dependence. By eliminating the need for daily medication, the treatment both reduces the burden on patients and lightens the workload for healthcare providers”, says Daniel Mate, Business Unit Head for Portugal and Spain. “Portugal is widely recognized as a global leader in the decriminalization of drug addiction, and now, we are proud to add to and support the destigmatization of opioid dependence by offering prolonged-release solutions to the challenges faced by those affected.”

Opioid dependence is a severe, chronic, and relapsing disease that profoundly affects both individuals and society, presenting a major challenge for healthcare systems worldwide.^1,2  In Portugal, opioid dependence has been increasing, with heroin continuing to be the most prevalent drug among patients in both outpatient treatment (66 percent) and detoxification units (61 percent). Over the past six years, the number of opioid-related overdose cases has reached the highest levels recorded since 2011. Additionally, methadone-related overdoses have become a growing concern, with the past three years showing the highest figures since 2008³, highlighting the urgent need for more effective treatment strategies.

Buvidal is indicated for the treatment of opioid dependence within a framework of medical, social and psychological treatment and is intended for use in adults and adolescents aged 16 years or over.⁴ Since its first launch in 2019, the product is today available in more than 20 countries in Europe, Australia, and the US. In the US, the product is marketed under the brand name Brixadi by Camurus’ licensee Braeburn.

For more information on Buvidal, see: https://buvidal.com/.

About Camurus
Camurus is an international, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for improving the lives of patients with severe and chronic diseases. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal^® technology and its extensive R&D expertise. The R&D pipeline includes products for the treatment of dependence, pain, cancer, and endocrine diseases. Camurus has operations across Europe, the US, and Australia, with headquarters in Lund, Sweden. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com and LinkedIn.

References

1. Volkow, ND. Medications for Opioid Use Disorder: Bridging the Gap in Care. N Engl J Med 2017; 377(4): 391–394.
2. Degenhardt, L., et al. Addiction. 2014; 109(8): 1320-1333.
3. Serviço de Intervenções nos Comportamentos Aditivos e nas Dependências. Relatório Anual 2023: A Situação do País em Matéria de Drogas e Toxicodependência. February 2025. Relatório Anual 2025 A Situação do País Em Materia de Drogas e Toxicodependencias (icad.pt)
4. Buvidal^® Product Information, March 2025.